Unnati Pharmax

Jakura 5mg Tablet
Composition: Tofacitinib 5mg
International Trade Name: Xeljanz®

Jakura 5 is a high-quality Tofacitinib 5mg Tablet, a trusted equivalent of the internationally recognized Janus kinase (JAK) inhibitor marketed under the brand name Xeljanz®. Manufactured in WHO-GMP certified facilities, Jakura Tablets are supplied by reputable pharmaceutical exporters from India to support global immunology, rheumatology, and dermatology treatment programs.

Tofacitinib selectively inhibits JAK1 and JAK3, modulating immune signaling pathways involved in inflammation. Jakura 5mg Tablet is primarily indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other approved autoimmune and inflammatory conditions in adults.

Keywords: Tofacitinib 5mg tablet, Jakura 5 tablet, Xeljanz equivalent, JAK inhibitor therapy, rheumatoid arthritis treatment, psoriatic arthritis therapy, ulcerative colitis management, immunology drug exporter India.

Jakura 5 Tofacitinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and bioavailability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for rheumatology clinics, dermatology centers, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Hydroxychloroquine Sulfate Tablet
Composition: Hydroxychloroquine Sulfate
International Trade Name: Plaquenil®

Hydroxychloroquine Sulfate Tablets are a high-quality formulation of hydroxychloroquine, a trusted equivalent of the internationally recognized antimalarial and disease-modifying antirheumatic drug marketed under the brand name Plaquenil®. Manufactured in WHO-GMP certified facilities, these tablets are supplied by reputable pharmaceutical exporters from India to support global malaria prevention, rheumatology, and autoimmune disease treatment programs.

Hydroxychloroquine Sulfate works by modulating immune system activity and interfering with lysosomal activity and antigen presentation. It also exhibits antimalarial effects by inhibiting parasite growth. These tablets are primarily indicated for the prevention and treatment of malaria and for managing autoimmune and inflammatory conditions such as rheumatoid arthritis, systemic lupus erythematosus, and other approved indications.

Keywords: Hydroxychloroquine sulfate tablet, Plaquenil equivalent, antimalarial therapy, autoimmune disease treatment, rheumatoid arthritis medication, lupus management, pharmaceutical exporter India.

Hydroxychloroquine Sulfate Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, clinics, government health programs, and international pharmaceutical distributors.

Mabtas 100 Injection
Composition: Rituximab 100mg/10ml (Solution for Infusion)
International Trade Name: Rituxan®

Mabtas 100 is a high-quality Rituximab 100mg/10ml Injection, a trusted biosimilar equivalent of the internationally recognized anti-CD20 monoclonal antibody marketed under the brand name Rituxan®. Manufactured in WHO-GMP certified facilities, Mabtas Injection is supplied by reputable pharmaceutical exporters from India to support advanced global oncology, hematology, and immunology treatment programs.

Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen on B-lymphocytes, leading to B-cell depletion and immune modulation. Mabtas 100mg Injection is primarily indicated for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (in combination with methotrexate), and other approved autoimmune and hematologic disorders.

Keywords: Rituximab 100mg injection, Mabtas 100 injection, Rituxan biosimilar, anti-CD20 monoclonal antibody, non-Hodgkin’s lymphoma therapy, CLL treatment, rheumatoid arthritis biologic, oncology biologics exporter India.

Mabtas 100 Rituximab Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, hematology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Mabtas 500 Injection
Composition: Rituximab Concentrate for Solution for Infusion 500mg
International Trade Name: Rituxan®

Mabtas 500 is a high-quality Rituximab 500mg Concentrate for Solution for Infusion, a trusted biosimilar equivalent of the internationally recognized anti-CD20 monoclonal antibody marketed under the brand name Rituxan®. Manufactured in WHO-GMP certified facilities, Mabtas Injection is supplied by reputable pharmaceutical exporters from India to support advanced global oncology, hematology, and immunology treatment programs.

Rituximab is a chimeric monoclonal antibody that selectively targets the CD20 antigen on B-lymphocytes, leading to B-cell depletion through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Mabtas 500 Injection is primarily indicated for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (in combination with methotrexate), and other approved autoimmune and hematologic disorders.

Keywords: Rituximab 500mg infusion, Mabtas 500 injection, Rituxan biosimilar, anti-CD20 monoclonal antibody, non-Hodgkin’s lymphoma therapy, CLL treatment, rheumatoid arthritis biologic, oncology biologics exporter India.

Mabtas 500 Rituximab Concentrate for Solution for Infusion is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The product is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, hematology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Maballa 500 Injection
Composition: Rituximab 500mg/10ml (Solution for Infusion)
International Trade Name: Rituxan®

Maballa 500 is a high-quality Rituximab 500mg/10ml Injection, a trusted biosimilar equivalent of the internationally recognized anti-CD20 monoclonal antibody marketed under the brand name Rituxan®. Manufactured in WHO-GMP certified facilities, Maballa Injection is supplied by reputable pharmaceutical exporters from India to support advanced global oncology, hematology, and immunology treatment programs.

Rituximab is a chimeric monoclonal antibody that targets the CD20 antigen on B-lymphocytes, leading to B-cell depletion and immune modulation. Maballa 500mg Injection is primarily indicated for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (in combination with methotrexate), and other approved autoimmune and hematologic disorders.

Keywords: Rituximab 500mg injection, Maballa 500 injection, Rituxan biosimilar, anti-CD20 monoclonal antibody, non-Hodgkin’s lymphoma therapy, CLL treatment, rheumatoid arthritis biologic, oncology biologics exporter India.

Maballa 500 Rituximab Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, hematology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Durolane Injection
Composition: Hyaluronic Acid (Sodium Hyaluronate)
International Trade Name: TriVisc®

Durolane is a high-quality Hyaluronic Acid-based intra-articular injection, a trusted equivalent of the internationally recognized viscosupplement marketed under the brand name TriVisc®. Manufactured in WHO-GMP certified facilities, Durolane Injection is supplied by reputable pharmaceutical exporters from India to support advanced global osteoarthritis and joint health treatment programs.

Hyaluronic Acid in Durolane acts as a viscoelastic supplement to synovial fluid, providing lubrication, shock absorption, and improved joint mobility. Durolane Injection is primarily indicated for the treatment of pain and functional impairment associated with osteoarthritis of the knee and other affected joints.

Keywords: Hyaluronic acid injection, Durolane injection, TriVisc equivalent, osteoarthritis treatment, joint health therapy, viscosupplement therapy, knee pain management, pharmaceutical exporter India.

Durolane Osteoarthritis Injection is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, sterile, export-grade packaging with complete regulatory documentation, making it suitable for orthopedic clinics, rheumatology centers, tertiary care hospitals, and international pharmaceutical distributors.

HQCGuard Tablet
Composition: Hydroxychloroquine
International Trade Name: Plaquenil®

HQCGuard is a high-quality Hydroxychloroquine Tablet, a trusted equivalent of the internationally recognized antimalarial and disease-modifying antirheumatic drug marketed under the brand name Plaquenil®. Manufactured in WHO-GMP certified facilities, HQCGuard Tablets are supplied by reputable pharmaceutical exporters from India to support global malaria prevention, rheumatology, and autoimmune disease treatment programs.

Hydroxychloroquine modulates immune system activity by interfering with lysosomal activity and antigen presentation, and it also exhibits antimalarial effects by inhibiting parasite growth. HQCGuard Tablets are primarily indicated for the treatment and prevention of malaria, as well as for autoimmune and inflammatory conditions including rheumatoid arthritis, systemic lupus erythematosus, and other approved indications.

Keywords: Hydroxychloroquine tablets, HQCGuard tablet, Plaquenil equivalent, antimalarial therapy, autoimmune disease treatment, rheumatoid arthritis medication, lupus management, pharmaceutical exporter India.

HQCGuard Hydroxychloroquine Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for hospitals, clinics, government health programs, and international pharmaceutical distributors.

Barijak 4mg Tablet
Composition: Baricitinib 4mg
International Trade Name: Olumiant®

Barijak 4 is a high-quality Baricitinib 4mg Tablet, a trusted equivalent of the internationally recognized Janus kinase (JAK) inhibitor marketed under the brand name Olumiant®. Manufactured in WHO-GMP certified facilities, Barijak Tablets are supplied by reputable pharmaceutical exporters from India to support advanced global immunology, rheumatology, and dermatology treatment programs.

Baricitinib is a selective JAK1 and JAK2 inhibitor that modulates immune signaling pathways involved in inflammation. Barijak 4mg Tablet is primarily indicated for the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response to one or more DMARDs, as well as for other approved inflammatory and autoimmune conditions.

Keywords: Baricitinib 4mg tablet, Barijak 4 tablet, Olumiant equivalent, JAK inhibitor therapy, rheumatoid arthritis treatment, autoimmune disease management, immunology drug exporter India.

Barijak 4 Baricitinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and bioavailability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for rheumatology clinics, dermatology centers, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Bonkaro Infusion
Composition: Zoledronic Acid
International Trade Name: Reclast®

Bonkaro is a high-quality Zoledronic Acid Infusion, a trusted equivalent of the internationally recognized bisphosphonate marketed under the brand name Reclast®. Manufactured in WHO-GMP certified facilities, Bonkaro Infusion is supplied by reputable pharmaceutical exporters from India to support global bone health and oncology supportive care treatment programs.

Zoledronic Acid is a potent bisphosphonate that inhibits osteoclast-mediated bone resorption, thereby strengthening bone structure and reducing fracture risk. Bonkaro Infusion is primarily indicated for the treatment and prevention of osteoporosis in postmenopausal women and men at increased risk of fractures, Paget’s disease of bone, and for reducing skeletal-related events in patients with bone metastases associated with solid tumors and multiple myeloma.

Keywords: Zoledronic Acid infusion, Bonkaro infusion, Reclast equivalent, bisphosphonate therapy, osteoporosis treatment, bone metastases management, skeletal-related event prevention, oncology supportive care, pharmaceutical exporter India.

Bonkaro Zoledronic Acid Infusion is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The infusion is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology centers, endocrinology clinics, orthopedic practices, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Cobix 200mg Capsule
Composition: Celecoxib 200mg
International Trade Name: Celebrex®

Cobix 200 is a high-quality Celecoxib 200mg Capsule, a trusted equivalent of the internationally recognized selective COX-2 inhibitor marketed under the brand name Celebrex®. Manufactured in WHO-GMP certified facilities, Cobix Capsules are supplied by reputable pharmaceutical exporters from India to support global pain management, rheumatology, and orthopedic treatment programs.

Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins responsible for pain and inflammation while minimizing gastrointestinal side effects associated with non-selective NSAIDs. Cobix 200mg Capsule is primarily indicated for the management of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, primary dysmenorrhea, and other approved inflammatory conditions.

Keywords: Celecoxib 200mg capsule, Cobix 200 capsule, Celebrex equivalent, COX-2 inhibitor, arthritis pain management, anti-inflammatory capsule, orthopedic pain treatment, pharmaceutical exporter India.

Cobix 200 Celecoxib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and bioavailability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for rheumatology clinics, orthopedic centers, pain management practices, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Naproheal 500mg Tablet
Composition: Naproxen 500mg
International Trade Name: Anaprox®

Naproheal 500 is a high-quality Naproxen 500mg Tablet IP, a trusted equivalent of the internationally recognized non-steroidal anti-inflammatory drug (NSAID) marketed under the brand name Anaprox®. Manufactured in WHO-GMP certified facilities, Naproheal Tablets are supplied by reputable pharmaceutical exporters from India to support global pain management, rheumatology, and musculoskeletal treatment programs.

Naproxen works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins responsible for pain, inflammation, and fever. Naproheal 500mg Tablet is primarily indicated for the management of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, gout, dysmenorrhea, and other approved inflammatory conditions.

Keywords: Naproxen 500mg tablet, Naproheal 500 tablet, Anaprox equivalent, NSAID therapy, arthritis pain management, anti-inflammatory medication, musculoskeletal pain treatment, pharmaceutical exporter India.

Naproheal 500 Naproxen Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and bioavailability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for rheumatology clinics, orthopedic centers, pain management practices, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Celeheal 200mg Capsule
Composition: Celecoxib 200mg
International Trade Name: Celebra®

Celeheal 200 is a high-quality Celecoxib 200mg Capsule, a trusted equivalent of the internationally recognized selective COX-2 inhibitor marketed under the brand name Celebra®. Manufactured in WHO-GMP certified facilities, Celeheal Capsules are supplied by reputable pharmaceutical exporters from India to support global pain management, rheumatology, and orthopedic treatment programs.

Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins responsible for pain and inflammation while minimizing gastrointestinal side effects associated with non-selective NSAIDs. Celeheal 200mg Capsule is primarily indicated for the management of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and other approved inflammatory conditions.

Keywords: Celecoxib 200mg capsule, Celeheal 200 capsule, Celebra equivalent, COX-2 inhibitor, arthritis pain management, anti-inflammatory capsule, orthopedic pain treatment, pharmaceutical exporter India.

Celeheal 200 Celecoxib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and bioavailability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for rheumatology clinics, orthopedic centers, pain management practices, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Zodlieva 4mg Injection
Composition: Zoledronic Acid Injection 4mg
International Trade Name: Reclast®

Zodlieva 4 is a high-quality Zoledronic Acid 4mg Injection, a trusted equivalent of the internationally recognized bisphosphonate marketed under the brand name Reclast®. Manufactured in WHO-GMP certified facilities, Zodlieva Injection is supplied by reputable pharmaceutical exporters from India to support global oncology supportive care and bone health treatment programs.

Zoledronic Acid is a potent bisphosphonate that inhibits osteoclast-mediated bone resorption, thereby reducing skeletal-related events and strengthening bone structure. Zodlieva 4mg Injection is primarily indicated for the prevention of skeletal complications in patients with bone metastases from solid tumors, multiple myeloma, treatment of hypercalcemia of malignancy, and other approved indications.

Keywords: Zoledronic Acid 4mg injection, Zodlieva 4 injection, Reclast equivalent, bisphosphonate therapy, bone metastases management, multiple myeloma supportive care, hypercalcemia of malignancy treatment, oncology injection exporter India.

Zodlieva Zoledronic Acid Injection 4mg is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Forteo Injection
Composition: Teriparatide
International Trade Name: Terifrac®

Forteo is a high-quality Teriparatide Injection, a trusted equivalent of the internationally recognized recombinant parathyroid hormone analog marketed under the brand name Terifrac®. Manufactured in WHO-GMP certified facilities, Forteo Injection is supplied by reputable pharmaceutical exporters from India to support global osteoporosis and bone health treatment programs.

Teriparatide is a recombinant form of human parathyroid hormone (PTH 1-34) that stimulates new bone formation by activating osteoblasts, thereby increasing bone mineral density and reducing fracture risk. Forteo Injection is primarily indicated for the treatment of osteoporosis in postmenopausal women, men at high risk of fracture, and in patients with glucocorticoid-induced osteoporosis.

Keywords: Teriparatide injection, Forteo injection, Terifrac equivalent, osteoporosis treatment, bone formation therapy, fracture risk reduction, recombinant PTH, pharmaceutical exporter India.

Forteo Teriparatide Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for endocrinology clinics, orthopedic practices, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Cyclophil-ME Capsule
Composition: Cyclosporine (Microemulsion)
International Trade Name: Sandimmun®

Cyclophil-ME is a high-quality Cyclosporine microemulsion formulation, a trusted equivalent of the internationally recognized immunosuppressant marketed under the brand name Sandimmun®. Manufactured in WHO-GMP certified facilities, Cyclophil-ME Capsules are supplied by reliable pharmaceutical exporters from India to support global transplant medicine, dermatology, and autoimmune disease treatment programs.

Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by inhibiting interleukin-2 production, thereby preventing immune-mediated tissue damage. Cyclophil-ME Capsules are primarily indicated for the prevention of organ transplant rejection, as well as for the management of severe rheumatoid arthritis, psoriasis, atopic dermatitis, nephrotic syndrome, and other autoimmune or inflammatory disorders.

Keywords: Cyclosporine capsules, Cyclophil-ME, Sandimmun equivalent, calcineurin inhibitor, immunosuppressant therapy, organ transplant medicine, autoimmune disease treatment, dermatology immunotherapy, pharmaceutical exporter India.

Cyclophil-ME Cyclosporine Capsules are manufactured under stringent GMP and quality standards, ensuring consistent bioavailability, efficacy, and safety. The product is supplied in secure, export-grade packaging with complete regulatory documentation, making it suitable for transplant centers, nephrology and dermatology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Zodlieva 4mg Injection
Composition: Zoledronic Acid Injection 4mg
International Trade Name: Reclast®

Zodlieva 4 is a high-quality Zoledronic Acid 4mg Injection, a trusted equivalent of the internationally recognized bisphosphonate marketed under the brand name Reclast®. Manufactured in WHO-GMP certified facilities, Zodlieva Injection is supplied by reputable pharmaceutical exporters from India to support global oncology supportive care and bone health treatment programs.

Zoledronic Acid is a potent bisphosphonate that inhibits osteoclast-mediated bone resorption, thereby reducing skeletal-related events and strengthening bone structure. Zodlieva 4mg Injection is primarily indicated for the prevention of skeletal complications in patients with bone metastases from solid tumors, multiple myeloma, treatment of hypercalcemia of malignancy, and other approved indications.

Keywords: Zoledronic Acid 4mg injection, Zodlieva 4 injection, Reclast equivalent, bisphosphonate therapy, bone metastases management, multiple myeloma supportive care, hypercalcemia of malignancy treatment, oncology injection exporter India.

Zodlieva Zoledronic Acid Injection 4mg is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Pomide 2mg Capsule
Composition: Pomalidomide 2mg
International Trade Name: Pomalyst®

Pomide 2 is a high-quality Pomalidomide 2mg Capsule, a trusted equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Pomalyst®. Manufactured in WHO-GMP certified facilities, Pomide Capsules are supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multiple myeloma management.

Pomalidomide is an immunomodulatory drug that exerts anti-proliferative and pro-apoptotic effects on malignant plasma cells while enhancing T-cell and natural killer (NK) cell-mediated immune responses. Pomide 2mg Capsule is primarily indicated for the treatment of relapsed or refractory multiple myeloma in patients who have received prior therapies including lenalidomide and bortezomib.

Keywords: Pomalidomide 2mg capsule, Pomide 2 capsule, Pomalyst equivalent, immunomodulatory drug (IMiD), multiple myeloma therapy, hematologic oncology treatment, anticancer capsule exporter India.

Pomide 2 Pomalidomide Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors

Pomalid Capsule
Composition: Pomalidomide
International Trade Name: Pomalyst®

Pomalid is a high-quality Pomalidomide Capsule, a trusted equivalent of the internationally recognized immunomodulatory agent marketed under the brand name Pomalyst®. Manufactured in WHO-GMP certified facilities, Pomalid Capsules are supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multiple myeloma management.

Pomalidomide is an immunomodulatory drug that exerts anti-proliferative and pro-apoptotic effects on malignant plasma cells while enhancing T-cell and natural killer (NK) cell-mediated immune responses. Pomalid Capsules are primarily indicated for the treatment of relapsed or refractory multiple myeloma in patients who have received prior therapies including lenalidomide and bortezomib.

Keywords: Pomalidomide capsule, Pomalid capsule, Pomalyst equivalent, immunomodulatory drug (IMiD), multiple myeloma therapy, hematologic oncology treatment, anticancer capsule exporter India.

Pomalid Pomalidomide Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology clinics, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Intacept 50 Injection
Composition: Etanercept 50mg/1.0ml (Solution for Injection)
International Trade Name: Enbrel®

Intacept 50 is a high-quality Etanercept 50mg/1.0ml Solution for Injection, a trusted biosimilar equivalent of the internationally recognized TNF-alpha inhibitor marketed under the brand name Enbrel®. Manufactured in WHO-GMP certified facilities, Intacept Injection is supplied by reputable pharmaceutical exporters from India to support advanced global immunology and rheumatology treatment programs.

Etanercept is a recombinant fusion protein that binds to tumor necrosis factor-alpha (TNF-α), inhibiting its interaction with cell surface receptors and reducing inflammatory responses. Intacept 50 Injection is primarily indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and juvenile idiopathic arthritis, either as monotherapy or in combination with disease-modifying antirheumatic drugs (DMARDs).

Keywords: Etanercept 50mg injection, Intacept 50 injection, Enbrel biosimilar, TNF alpha inhibitor, rheumatoid arthritis treatment, ankylosing spondylitis therapy, psoriasis biologic injection, immunology biologics exporter India.

Intacept 50 Etanercept Injection is manufactured under stringent GMP and biologics quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for rheumatology clinics, dermatology centers, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Olumiant 4mg Tablet
Composition: Baricitinib 4mg
International Trade Name: Olumiant®

Olumiant 4 is a high-quality Baricitinib 4mg Tablet, a trusted internationally recognized Janus kinase (JAK) inhibitor marketed under the brand name Olumiant®. Manufactured in WHO-GMP certified facilities, Olumiant Tablets are supplied by reputable pharmaceutical exporters from India to support global immunology, rheumatology, and dermatology treatment programs.

Baricitinib selectively inhibits JAK1 and JAK2, modulating intracellular signaling pathways involved in inflammation and immune responses. Olumiant 4mg Tablet is primarily indicated for the treatment of moderate to severe rheumatoid arthritis in adults with inadequate response to one or more DMARDs, as well as for other approved autoimmune and inflammatory conditions.

Keywords: Baricitinib 4mg tablet, Olumiant 4 tablet, JAK inhibitor therapy, rheumatoid arthritis treatment, autoimmune disease management, immunology drug exporter India, Olumiant equivalent.

Olumiant 4 Baricitinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and bioavailability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for rheumatology clinics, dermatology centers, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Bandrone 150mg Tablet
Composition: Ibandronic Acid 150mg
International Trade Name: Boniva®

Bandrone 150 is a high-quality Ibandronic Acid 150mg Tablet, a trusted equivalent of the internationally recognized bisphosphonate marketed under the brand name Boniva®. Manufactured in WHO-GMP certified facilities, Bandrone Tablets are supplied by reputable pharmaceutical exporters from India to support global bone health and osteoporosis treatment programs.

Ibandronic Acid is a potent bisphosphonate that inhibits osteoclast-mediated bone resorption, thereby improving bone density and reducing the risk of fractures. Bandrone 150mg Tablet is primarily indicated for the prevention and treatment of postmenopausal osteoporosis in women at increased risk of fractures.

Keywords: Ibandronic Acid 150mg tablet, Bandrone 150 tablet, Boniva equivalent, bisphosphonate therapy, osteoporosis treatment, fracture risk reduction, bone health medication, pharmaceutical exporter India.

Bandrone 150 Ibandronic Acid Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for endocrinology clinics, orthopedic practices, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Arpimune-O 100mg Capsule
Composition: Ciclosporin (Cyclosporine) 100mg
International Trade Name: Sandimmune®

Arpimune-O 100 is a high-quality Ciclosporin 100mg Capsule, a trusted equivalent of the internationally recognized immunosuppressant marketed under the brand name Sandimmune®. Manufactured in WHO-GMP certified facilities, Arpimune-O Capsules are supplied by reputable pharmaceutical exporters from India to support global transplant medicine and autoimmune disease treatment programs.

Ciclosporin is a potent calcineurin inhibitor that suppresses T-cell activation by inhibiting interleukin-2 production, thereby reducing immune-mediated responses. Arpimune-O 100mg Capsule is primarily indicated for the prevention of organ transplant rejection and for the treatment of severe autoimmune and inflammatory conditions such as psoriasis, rheumatoid arthritis, atopic dermatitis, nephrotic syndrome, and other approved indications.

Keywords: Ciclosporin 100mg capsule, Arpimune-O 100, Sandimmune equivalent, calcineurin inhibitor, immunosuppressant therapy, organ transplant medicine, autoimmune disease treatment, dermatology immunotherapy, pharmaceutical exporter India.

Arpimune-O 100 Ciclosporin Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and bioavailability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for transplant centers, nephrology and dermatology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Azoran 50mg Tablet
Composition: Azathioprine Tablets IP 50mg
International Trade Name: Imuran®

Azoran 50 is a high-quality Azathioprine 50mg Tablet IP, a trusted equivalent of the internationally recognized immunosuppressant and antimetabolite agent marketed under the brand name Imuran®. Manufactured in WHO-GMP certified facilities, Azoran Tablets are supplied by reputable pharmaceutical exporters from India to support global transplant medicine, gastroenterology, and autoimmune disease treatment programs.

Azathioprine is a purine analog that interferes with DNA synthesis and suppresses immune cell proliferation. Azoran 50mg Tablet is primarily indicated for the prevention of organ transplant rejection and for the management of autoimmune and inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), systemic lupus erythematosus, and other approved indications.

Keywords: Azathioprine 50mg tablet, Azoran 50 tablet, Imuran equivalent, immunosuppressant therapy, organ transplant medicine, autoimmune disease treatment, inflammatory bowel disease therapy, pharmaceutical exporter India.

Azoran 50 Azathioprine Tablets IP are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for transplant centers, gastroenterology clinics, rheumatology practices, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Fluromyra Injection 500mg/10ml
Composition: Fluorouracil Injection IP 500mg/10ml
International Trade Name: Adrucil®

Fluromyra is a high-quality Fluorouracil (5-FU) Injection IP 500mg/10ml, a trusted biosimilar equivalent of the internationally recognized antimetabolite chemotherapeutic agent marketed under the brand name Adrucil®. Manufactured in WHO-GMP certified facilities, Fluromyra Injection is supplied by reputable pharmaceutical exporters from India to support advanced global oncology treatment programs across solid tumor indications.

Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase, thereby disrupting DNA and RNA synthesis in rapidly dividing cancer cells. Fluromyra 500mg/10ml Injection is primarily indicated for the treatment of colorectal cancer, breast cancer, gastric cancer, pancreatic cancer, head and neck cancers, and other approved solid tumors, either as monotherapy or in combination chemotherapy regimens.

Keywords: Fluorouracil 500mg injection, Fluromyra injection, Adrucil biosimilar, 5-FU chemotherapy, antimetabolite oncology injection, colorectal cancer treatment, breast cancer chemotherapy, anticancer injectable exporter India, oncology drug manufacturer India.

Fluromyra Fluorouracil Injection IP is manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The injection is supplied in secure, cold-chain compliant, export-grade packaging with complete regulatory documentation, making it suitable for oncology infusion centers, tertiary care hospitals, government cancer programs, and international pharmaceutical distributors.

Arpimune-O 50mg Capsule
Composition: Ciclosporin (Cyclosporine) 50mg
International Trade Name: Sandimmune®

Arpimune-O 50 is a high-quality Ciclosporin 50mg Capsule, a trusted equivalent of the internationally recognized immunosuppressant marketed under the brand name Sandimmune®. Manufactured in WHO-GMP certified facilities, Arpimune-O Capsules are supplied by reputable pharmaceutical exporters from India to support global transplant medicine and autoimmune disease treatment programs.

Ciclosporin is a potent calcineurin inhibitor that suppresses T-cell activation by inhibiting interleukin-2 production, thereby reducing immune-mediated responses. Arpimune-O 50mg Capsule is primarily indicated for the prevention of organ transplant rejection and for the treatment of severe autoimmune and inflammatory conditions such as psoriasis, rheumatoid arthritis, atopic dermatitis, nephrotic syndrome, and other approved indications.

Keywords: Ciclosporin 50mg capsule, Arpimune-O 50, Sandimmune equivalent, calcineurin inhibitor, immunosuppressant therapy, organ transplant medicine, autoimmune disease treatment, dermatology immunotherapy, pharmaceutical exporter India.

Arpimune-O 50 Ciclosporin Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and bioavailability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for transplant centers, nephrology and dermatology clinics, tertiary care hospitals, government health programs, and international pharmaceutical distributors.

Tofajak 5mg Tablet
Composition: Tofacitinib 5mg
International Trade Name: Xeljanz®

Tofajak 5 is a high-quality Tofacitinib 5mg Tablet, a trusted equivalent of the internationally recognized Janus kinase (JAK) inhibitor marketed under the brand name Xeljanz®. Manufactured in WHO-GMP certified facilities, Tofajak Tablets are supplied by reputable pharmaceutical exporters from India to support advanced global immunology and rheumatology treatment programs.

Tofacitinib is a selective JAK inhibitor that modulates immune response by inhibiting intracellular signaling pathways involved in inflammation. Tofajak 5mg Tablet is primarily indicated for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and other approved autoimmune and inflammatory conditions.

Keywords: Tofacitinib 5mg tablet, Tofajak 5 tablet, Xeljanz equivalent, JAK inhibitor therapy, rheumatoid arthritis treatment, ulcerative colitis management, psoriatic arthritis therapy, immunology drug exporter India.

Tofajak 5 Tofacitinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and bioavailability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for rheumatology clinics, gastroenterology practices, tertiary care hospitals, government health programs, and international pharmaceutical distributors.